Raipur: Amid the raging debate over the approval to
India’s Covaxin, health minister TS Singh Deo said that the state government
will not procure Covaxin manufactured by Bharat Biotech until its trials are
He further added that the Covaxin has not completed its Phase III trials yet and is completely risky for the common people. “If the central government sends this vaccine to Chhattisgarh, we will refuse it”, he said.
The health minister said that as many as 2 vaccines have been approved for use in India including Oxford’s Covishield which is being developed here by Serum Institute of India and another one is indigenously developed Covaxin whose third trials are yet to be completed but have got approval for emergency use in India.
Shedding light over the incident of death of a volunteer who received the shot of Covaxin, Singh Deo said that such an incident questions the safety claims of this vaccine. “The central government should not hurry in this matter. Vaccination has to last for at least 500 to 700 days in the country. If the decision is based on the results of the trial, then people's trust in the vaccine will increase”, he said.
The health minister further said that in the third trial of Covaxin, 28000 samples were to be taken; however, 23,000 have been taken. “In such a situation, its results are doubtful. If the vaccine is allowed to be used without meeting the trial and safety criteria, then other companies will also come to seek the permission with incomplete trials”, he said.
Meanwhile, just two days ago parliamentary secretary and MLA Vikas Upadhyay questioned the process of allowing the Covaxin. Upadhyay has alleged that the central government has given permission to this vaccine by putting pressure on the drug regulator so that they can show themselves in the competition of other countries.